🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

307 results for “Disc Medicine” Clear

  1. LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1

    Disc Medicine

    B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-Hodgkin B-cell lymphoma

    phase 2 small molecule active

    1 trial

  2. Late immunity following single immunization with GA2 sporozoites (GACHA)

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  3. Leflunomide CF 20 mg, filmomhulde tabletten, Hydorxychloroquine 200mg/Placebo, Hydroxychloroquinesulfaat 200 mg Focus, filmomhulde tabletten, Hydroxychloroquinesulfaat CF 200 mg, filmomhulde tabletten, Leflunomide Mylan 10 mg, filmomhulde tabletten, Leflunomide 20mg/Placebo, Leflunomide Mylan 20 mg, filmomhulde tabletten, Plaquenil 200 mg, filmomhulde tabletten

    Disc Medicine

    primary Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  4. Lysergide D-tartrate, Placebo for Lysergide tartrate oral solution

    Disc Medicine

    Chronic cluster headache

    phase 2 small molecule active

    1 trial

  5. Matching placebo for Survodutide, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  6. Mekinist 0.5 mg film-coated tablets

    Disc Medicine

    Neurofibromatosis type 1

    phase 2 small molecule active

    1 trial

  7. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  8. Mesenchymal stem cells, Suspension and solvent for suspension for injection

    Disc Medicine

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  9. Mineral-enriched powder

    Disc Medicine

    Iron Deficiency

    phase 2 other completed

    1 trial

  10. NIVOLUMAB

    Disc Medicine

    Peritoneal Mesothelioma

    phase 2 small molecule active

    1 trial

  11. NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  12. NaCl 0,9%, Deferoxamine Noridem 500mg Κόνις για ενέσιμο διάλυμα ή διάλυμα για έγχυση

    Disc Medicine

    Subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  13. Natriumthiosulfat 25%

    Disc Medicine

    Raynaud’s phenomenon

    phase 2 small molecule active

    1 trial

  14. OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89

    Disc Medicine

    Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.

    phase 2 small molecule active

    1 trial

  15. Olaparib, Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  16. PEGINTERFERON ALFA-2A , TIL cells, Zirconium Zr 89 crefmirlimab berdoxam

    Disc Medicine

    Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  17. PYRIMETHAMINE, LENALIDOMIDE, PANOBINOSTAT

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  18. Padcev 30 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Padcev 20 mg powder for concentrate for solution for infusion

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  19. Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie

    Disc Medicine

    MDS with excess blasts, MDS/AML or AML patients

    phase 2 small molecule active

    1 trial

  20. Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg

    Disc Medicine

    Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).

    phase 2 small molecule active

    1 trial

  21. RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

    Disc Medicine

    Myelofibrosis

    phase 2 other active

    1 trial

  22. Rybelsus 7 mg tablets, Kerendia 20 mg film-coated tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  23. Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

    Disc Medicine

    Limited metastatic pancreatic cancer

    phase 2 other active

    1 trial

  24. Saphnelo 300 mg concentrate for solution for infusion, Saphnelo placebo

    Disc Medicine

    Sjogren's disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources